{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:23:34Z","timestamp":1790810614470,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s40265-020-01291-2","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T10:04:01Z","timestamp":1584007441000},"page":"609-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Delgocitinib: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"2","key":"1291_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section\u00a01. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351.","journal-title":"J Am Acad Dermatol."},{"issue":"10","key":"1291_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/1346-8138.13392","volume":"43","author":"H Saeki","year":"2016","unstructured":"Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the management of atopicd dermatitis 2016. J Dermatol. 2016;43(10):1117\u201345.","journal-title":"J Dermatol."},{"issue":"1","key":"1291_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section\u00a02. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol."},{"key":"1291_CR4","unstructured":"Japan Tobacco Inc. CORECTIM\u00ae Ointment 0.5% [Japanese Prescribing Information]. 2020. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/530614_26997A2M1020_1_02. Accessed 19 Feb 2020."},{"key":"1291_CR5","unstructured":"LEO Pharma. LEO Pharma and Japan Tobacco enter into license agreement for novel JAK inhibitor drug candidate [media release]. 4 Nov 2014. http:\/\/www.leo-pharma.com."},{"key":"1291_CR6","unstructured":"Japan Tobacco. JT and Torii sign exclusive license agreement for development and commercialization of JAK inhibitor in Japan [media release]. 28 Oct 2016. http:\/\/www.jt.com."},{"key":"1291_CR7","unstructured":"Japan Tobacco. JT signs exclusive license agreement with ROHTO Pharmaceutical for the development and commercialization of JAK inhibitor in Japan [media release]. 15 Mar 2018. http:\/\/www.jt.com."},{"issue":"1","key":"1291_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41\u201351.","journal-title":"Inflamm Res."},{"issue":"1","key":"1291_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/exd.13370","volume":"27","author":"A Tanimoto","year":"2018","unstructured":"Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22\u20139.","journal-title":"Exp Dermatol."},{"issue":"3","key":"1291_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","volume":"136","author":"W Amano","year":"2015","unstructured":"Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667\u201377.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"1291_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","volume":"84","author":"W Amano","year":"2016","unstructured":"Amano W, Nakajima S, Yamamoto Y, et al. JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation. J Dermatol Sci. 2016;84(3):258\u201365.","journal-title":"J Dermatol Sci."},{"issue":"6","key":"1291_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1346-8138.14322","volume":"45","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Yamada H, et al. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45(6):701\u20139.","journal-title":"J Dermatol."},{"key":"1291_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.015","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.015.","journal-title":"J Am Acad Dermatol."},{"key":"1291_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15173","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2019. https:\/\/doi.org\/10.1111\/1346-8138.15173.","journal-title":"J Dermatol."},{"key":"1291_CR15","unstructured":"Torii Pharmaceutical. Top-line results of JTE-052 ointment, JAK inhibitor, phase 3 clinical study in pediatric patients with atopic dermatitis (comparative study) in Japan [media release]. 25 Apr 2019. https:\/\/www.torii.co.jp\/en\/."},{"issue":"2","key":"1291_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bjd.16014","volume":"178","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424\u201332.","journal-title":"Br J Dermatol."},{"issue":"6","key":"1291_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","volume":"144","author":"H Nakagawa","year":"2019","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(6):1575\u201383.","journal-title":"J Allergy Clin Immunol."},{"key":"1291_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18469","author":"M Worm","year":"2019","unstructured":"Worm M, Bauer A, Elsner P, et al. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18469.","journal-title":"Br J Dermatol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01291-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01291-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T20:02:29Z","timestamp":1615492949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01291-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1291"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01291-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"12 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Dhillon is a contracted employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}